Figure 2.
Forest plot representing subgroup analysis of ORR per IRC assessment based on Lugano classification (15) for patients with MZL in the MAGNOLIA study (BGB-3111–214). CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone. aTwo-sided Clopper–Pearson 95% CIs for ORR.